PAVmed (PAVM) Q2 2025 earnings summary

Executive summary

• Stabilized corporate structure and strengthened balance sheet, positioning as a diversified life sciences company with independently financed subsidiaries under a shared services model.

• Lucid Diagnostics processed 2,756 EsoGuard tests, recognized $1.2 million in revenue, secured new insurance coverage, and scheduled a Medicare LCD CAC meeting.

• Veris Health completed $2.5 million in equity financing, relaunched development of its implantable physiological monitor, and began integration with OSU - The James for commercial launch.

• Management fee income from Lucid was $3.2 million in Q2 2025, following its deconsolidation.

• Ongoing efforts to raise capital for internal incubator projects and active pursuit of new promising assets, especially in biopharma and esophageal disease.

Financial highlights

• Lucid's EsoGuard test volume reached 2,756, with revenue rising 40% sequentially to $1.2 million for the quarter.

• Q2 2025 revenue and management fee income totaled $3.16 million, down $0.32 million year-over-year.

• GAAP net loss attributable to common stockholders was $13.3 million, or $(0.74) per diluted share.

• Non-GAAP adjusted loss for Q2 2025 was $1.8 million, or $(0.11) per share.

• Cash and cash equivalents stood at $4.0 million as of June 30, 2025, up from $1.2 million at year-end 2024.

Outlook and guidance

• Lucid is positioned for accelerated commercialization pending Medicare coverage and is expanding commercial insurance coverage and partnerships.

• Veris is advancing toward FDA clearance and commercial deployment of its implantable monitor, with plans to expand operations and integrate AI-enabled clinical decision support.

• Substantial doubt exists about the ability to continue as a going concern over the next 12 months without additional capital.

• Ongoing evaluation of new opportunities to leverage the shared services model and diversify the portfolio.